Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro(®)), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention

BACKGROUND: High-risk percutaneous coronary interventions (PCIs) are associated with a high complication rate, a low procedural success rate and a high restenosis rate, especially in diabetics. We sought to determine whether abciximab (ReoPro(®)) therapy affects long-term clinical outcomes of Korean...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Korean J Intern Med
Asıl Yazarlar: Sim, Doo Sun, Jeong, Myung Ho, Kim, Weon, Rhew, Jay Young, Yum, Ju Hyup, Kim, Ju Han, Cho, Jeong Gwan, Ahn, Young Keun, Park, Jong Chun, Ahn, Byoung Hee, Kim, Sang Hyung, Kang, Jung Chaee
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Korean Association of Internal Medicine 2003
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4531627/
https://ncbi.nlm.nih.gov/pubmed/14619381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2003.18.3.129
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller